Conference
P135 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301
| العنوان: | P135 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301 |
|---|---|
| المؤلفون: | Lampertico, Pietro, Aleman, Soo, Brunetto, Maurizia, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Chee, Grace M, Manuilov, Dmitry, Li, Mingyang, Geoghegan, Orla, Lau, Audrey H, Osinusi, Anu, Wiesch, Julian Schulze zur, Cornberg, Markus, Zeuzem, Stefan, Wedemeyer, Heiner |
| المصدر: | P135 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301 ; page A96-A97 |
| بيانات النشر: | BMJ Publishing Group Ltd and British Society of Gastroenterology |
| سنة النشر: | 2024 |
| نوع الوثيقة: | conference object |
| اللغة: | unknown |
| DOI: | 10.1136/gutjnl-2024-basl.137 |
| DOI: | 10.1136/gutjnl-2024-BASL.137 |
| الاتاحة: | http://dx.doi.org/10.1136/gutjnl-2024-basl.137 https://syndication.highwire.org/content/doi/10.1136/gutjnl-2024-BASL.137 |
| رقم الانضمام: | edsbas.8560B620 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/gutjnl-2024-basl.137 |
|---|